Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
28-29
|
pubmed:dateCreated |
1987-9-1
|
pubmed:abstractText |
For 176 patients seen between 1976 and 1984, with a mean age of 65 years, the probability of survival after ten years was 56% for lymphoplasmocytoid (n = 86), lymphoplasmocytic (n = 38) and non-classifiable (n = 10) subtypes, while it was 0% at the end of 6.5 years for the polymorph cell type (n = 42). Patients up to 60 years of age had, at 68%, a generally better prognosis than older ones, at only 30%. Cases with bone-marrow infiltration or leukemic washout (n = 114) were, like chronic lymphoid leukemia cases, classified according to the scheme of Rai and co-workers, while the remaining cases (n = 62) were classified according to the Ann Arbor scheme. There was a three-step prognosis of ten-year probability of 85% for stages I A, Rai 0, Rai I (n = 49), 50% for II A/B, III A, Rai II (n = 43), and 27% for III B/IV B and Rai III/IV (n = 41) of the non-polymorph cell subtypes. For the polymorph cell forms there was also a triple division with 88%, 53% and 14% after only four years. Additional unfavorable factors were rapid lymphoma growth, leukemic course, high paraprotein gradient and autoimmune hemolysis. The flexible employment of polychemotherapy and large-field radiotherapy, adapted to the mentioned unfavorable risk factors and age, contributed to the improved results in this heterogeneous group.
|
pubmed:language |
ger
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0012-0472
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
10
|
pubmed:volume |
112
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1116-20
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3608833-Adult,
pubmed-meshheading:3608833-Aged,
pubmed-meshheading:3608833-Aged, 80 and over,
pubmed-meshheading:3608833-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:3608833-Female,
pubmed-meshheading:3608833-Humans,
pubmed-meshheading:3608833-Lymphoma, Non-Hodgkin,
pubmed-meshheading:3608833-Male,
pubmed-meshheading:3608833-Middle Aged,
pubmed-meshheading:3608833-Prognosis,
pubmed-meshheading:3608833-Risk
|
pubmed:year |
1987
|
pubmed:articleTitle |
[Risk-adapted treatment of immunocytomas].
|
pubmed:publicationType |
Journal Article,
English Abstract
|